31,406 Shares in Stryker Corporation $SYK Purchased by Trust Co. of Vermont

Key Points

• Trust Co. of Vermont purchased 31,406 Stryker shares during the second quarter, valued at approximately $9.9 million. Institutional investors now own 77.09% of the company.
• Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $386.28, despite several firms recently lowering their targets.
• Stryker exceeded quarterly earnings expectations, reporting $3.69 in EPS and $6.59 billion in revenue, while revenue rose 9.4% year over year. The company also declared a quarterly dividend of $0.88 per share.

Trust Co. of Vermont purchased a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 31,406 shares of the medical technology company's stock, valued at approximately $9,888,000.

Several other large investors also recently modified their holdings of SYK. VanderPol Investments L.L.C. raised its holdings in shares of Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock worth $732,000 after buying an additional 28 shares in the last quarter. KCM Investment Advisors LLC boosted its stake in Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock valued at $653,000 after buying an additional 28 shares in the last quarter. Rossby Financial LCC grew its position in Stryker by 6.6% in the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock valued at $159,000 after acquiring an additional 28 shares during the period. Tcfg Wealth Management LLC grew its position in Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock valued at $403,000 after acquiring an additional 29 shares during the period. Finally, West Michigan Advisors LLC raised its stake in Stryker by 0.4% during the fourth quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company's stock worth $2,631,000 after acquiring an additional 30 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Leerink Partners lowered their target price on shares of Stryker from $410.00 to $407.00 and set an "outperform" rating on the stock in a report on Friday, June 5th. Sanford C. Bernstein set a $410.00 price target on Stryker in a report on Friday, May 1st. Evercore set a $350.00 price objective on shares of Stryker in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a research note on Friday, May 1st. Finally, Canaccord Genuity Group decreased their price target on shares of Stryker from $435.00 to $400.00 and set a "buy" rating on the stock in a research note on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.

Stryker Stock Performance

Stryker stock opened at $331.75 on Tuesday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a market cap of $127.25 billion, a PE ratio of 34.38, a PEG ratio of 2.16 and a beta of 0.76. The company's 50-day moving average is $325.21 and its two-hundred day moving average is $333.24.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. During the same quarter in the previous year, the company earned $3.13 EPS. Stryker's revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Insider Buying and Selling at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company's stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm's stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.60% of the stock is owned by company insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source